Small molecule therapeutics for treatment of neuropsychiatric disorders
- Summary
- Glial cell line-derived neurotropic factor (GDNF) is an essential protein for the growth, development, and plasticity of dopaminergic and motor neurons. Elevated GDNF levels are associated with decreased risk for neuropsychiatric disorders, including addiction and depression. This technology describes a class of organic molecules designed to specifically elevate GDNF levels in the brain. By selectively inducing GDNF, the small molecules identified in this technology can be potentially used as a treatment for alcohol abuse, depression, Parkinson's disease, and other neuropsychiatric disorders.
- Technology Benefits
- These small molecules specifically induce GDNF production without interfering with other signaling pathways in the brainReduced risk of side effectsPatent Information:Patent Pending (WO/2013/028999)Patent Pending (US 20150056699)Tech Ventures Reference: IR M11-026
- Technology Application
- Potential treatment for alcohol, drug, and other addictionsPotential treatment for depressionPotential treatment for Parkinson's diseasePotential treatment for neuropathic painResearch tool for studying GDNF expression
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Beth KaudererColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- m11-026
- *Principal Investigator
-
- *Publications
- Gassaway MM, Jacques TL, Kruegel AC, Karpowicz RJ Jr, Li X, Li S, Myer Y, Sames D1. "Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound." ACS Chem Biol. 2016 Jan 15;11(1):77-87.
- Country/Region
- USA
For more information, please click Here
